123 related articles for article (PubMed ID: 7895301)
1. A sensitive postcolumn derivatization/UV detection system for HPLC determination of antitumor divalent and quadrivalent platinum complexes.
Kizu R; Yamamoto T; Yokoyama T; Tanaka M; Miyazaki M
Chem Pharm Bull (Tokyo); 1995 Jan; 43(1):108-14. PubMed ID: 7895301
[TBL] [Abstract][Full Text] [Related]
2. Capillary liquid chromatography with UV detection using N,N-diethyl dithiocarbamate for determining platinum-based antitumor drugs in plasma.
Otsuki Y; Kotani A; Kusu F
Chem Pharm Bull (Tokyo); 2012; 60(5):665-9. PubMed ID: 22689405
[TBL] [Abstract][Full Text] [Related]
3. Analysis of antitumour [1,1-bis(aminomethyl)cyclohexane]platinum(II) complexes derived from spiroplatin by high-performance liquid chromatography with differential pulse amperometric detection.
Elferink F; van der Vijgh WJ; Pinedo HM
J Chromatogr; 1985 Mar; 320(2):379-92. PubMed ID: 4030937
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of (glycolate-0,0')-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin.
Sasaki Y; Tamura T; Eguchi K; Shinkai T; Fujiwara Y; Fukuda M; Ohe Y; Bungo M; Horichi N; Niimi S
Cancer Chemother Pharmacol; 1989; 23(4):243-6. PubMed ID: 2647312
[TBL] [Abstract][Full Text] [Related]
5. Quality control of pharmaceutical formulations containing cisplatin, carboplatin, and oxaliplatin by micellar and microemulsion electrokinetic chromatography (MEKC, MEEKC).
Nussbaumer S; Fleury-Souverain S; Schappler J; Rudaz S; Veuthey JL; Bonnabry P
J Pharm Biomed Anal; 2011 May; 55(2):253-8. PubMed ID: 21330090
[TBL] [Abstract][Full Text] [Related]
6. High-performance liquid chromatographic determination of cisplatin as platinum(II) in a pharmaceutical preparation and blood samples of cancer patients.
Khuhawar MY; Lanjwani SN; Memon SA
J Chromatogr B Biomed Sci Appl; 1997 May; 693(1):175-9. PubMed ID: 9200532
[TBL] [Abstract][Full Text] [Related]
7. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate.
Brouwers EE; Tibben MM; Rosing H; Hillebrand MJ; Joerger M; Schellens JH; Beijnen JH
J Mass Spectrom; 2006 Sep; 41(9):1186-94. PubMed ID: 16929560
[TBL] [Abstract][Full Text] [Related]
8. The tissue distribution in mice and pharmacokinetics in rabbits of oxaliplatin liposome.
Liu XP; Geng DQ; Xu HX; Sui XH
J Liposome Res; 2009; 19(4):278-86. PubMed ID: 19863163
[TBL] [Abstract][Full Text] [Related]
9. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
Jacobs SS; Fox E; Dennie C; Morgan LB; McCully CL; Balis FM
Clin Cancer Res; 2005 Feb; 11(4):1669-74. PubMed ID: 15746072
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacokinetic properties of platinium derivatives].
Boisdron-Celle M; Lebouil A; Allain P; Gamelin E
Bull Cancer; 2001 Aug; 88 Spec No():S14-9. PubMed ID: 11567909
[TBL] [Abstract][Full Text] [Related]
11. Determination of intact oxaliplatin in human plasma using high performance liquid chromatography-tandem mass spectrometry.
Zhang W; Seymour L; Chen EX
J Chromatogr B Analyt Technol Biomed Life Sci; 2008 Dec; 876(2):277-82. PubMed ID: 19026601
[TBL] [Abstract][Full Text] [Related]
12. Determination of cisplatin and related platinum complexes in plasma ultrafiltrate and urine by high-performance liquid chromatography with on-line radioactivity detection.
Baldew GS; Volkers KJ; De Goeij JJ; Vermeulen NP
J Chromatogr; 1989 Jun; 491(1):163-74. PubMed ID: 2793971
[TBL] [Abstract][Full Text] [Related]
13. Using HPLC for the determination of platinum drugs in biological matrixes after derivatization with diethyldithiocarbamate.
Turoňová D; Krčmová LK; Vošmik M; Melichar B; Švec F
J Sep Sci; 2023 Oct; 46(19):e2300392. PubMed ID: 37515359
[TBL] [Abstract][Full Text] [Related]
14. Liquid chromatographic procedure for the quantitative analysis of carboplatin in beagle dog plasma ultrafiltrate.
Duncan GF; Faulkner HC; Farmen RH; Pittman KA
J Pharm Sci; 1988 Mar; 77(3):273-6. PubMed ID: 3286860
[TBL] [Abstract][Full Text] [Related]
15. Accumulation, fractionation, and analysis of platinum in toxicologically affected tissues after cisplatin, oxaliplatin, and carboplatin administration.
Esteban-Fernández D; Verdaguer JM; Ramírez-Camacho R; Palacios MA; Gómez-Gómez MM
J Anal Toxicol; 2008 Mar; 32(2):140-6. PubMed ID: 18334097
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of a novel platinum anticancer compound HJ5 by high performance liquid chromatography].
Liu Y; He J; Liu ZD; Chen XZ; Liu WP
Se Pu; 2002 Jul; 20(4):345-7. PubMed ID: 12541919
[TBL] [Abstract][Full Text] [Related]
17. The interaction of platinum-based drugs with native biologically relevant proteins.
Brauckmann C; Wehe CA; Kieshauer M; Lanvers-Kaminsky C; Sperling M; Karst U
Anal Bioanal Chem; 2013 Feb; 405(6):1855-64. PubMed ID: 23052861
[TBL] [Abstract][Full Text] [Related]
18. High-performance liquid chromatographic procedures for the analysis of carboplatin in human plasma and urine.
Gaver RC; Deeb G
Cancer Chemother Pharmacol; 1986; 16(3):201-6. PubMed ID: 3516429
[TBL] [Abstract][Full Text] [Related]
19. DNA interactions of antitumor platinum(IV) complexes.
Nováková O; Vrána O; Kiseleva VI; Brabec V
Eur J Biochem; 1995 Mar; 228(3):616-24. PubMed ID: 7737155
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of (1R,2R-diaminocyclohexane)oxalatoplatinum(II) in comparison with cisplatin following a single intravenous injection in rabbits.
Kizu R; Higashi S; Kidani Y; Miyazaki M
Cancer Chemother Pharmacol; 1993; 31(6):475-80. PubMed ID: 8453687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
